Lone H. Ottesen
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
Journal: Targeted oncology
Published: September 11, 2024
Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors.
Journal: Future oncology (London, England)
Published: August 17, 2023
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: March 15, 2023
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Journal: Cancer chemotherapy and pharmacology
Published: March 13, 2023
Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 24, 2022
A Comprehensive Methodology to Systematically Identify Drug Hypersensitivity and Anaphylactic Reactions in Clinical Trial Databases.
Journal: Pharmaceutical medicine
Published: September 25, 2020
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Journal: JAMA oncology
Published: May 30, 2020
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: February 17, 2020
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Journal: The Lancet. Oncology
Published: September 23, 2019
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 15, 2016
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: December 17, 2015
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Journal: Molecular cancer therapeutics
Published: December 16, 2014
Last Updated: 09/26/2026